Real-world status of treatment for lymphoid neoplasms developed during the course of myeloproliferative neoplasms in Japan

Figures & data

Figure 1. Trial profile.

Table 1. Clinical characteristics of patients with MPNs and lymphoid neoplasms.

	Total (n = 24)		PV (n = 8)		ET (n = 14)		PMF (n = 2)
Raw percentages			33.3%		58.3%		8.3%
Male, n (%)	17	(70.8)	4	(50.0)	11	(78.6)	2	(100)
Age in years at the diagnosis of MPN, median (range)	68 (39-86)		64.5 (53-75)		67.5 (39-86)		68 (68-68)
JAK2V617F, n (%)	17/21*^1	(81.0)	8	(100)	7/11*^2	(63.6)	2	(100)
Therapy for MPNs
Cytoreductive therapy, n (%)	21	(87.5)	7		12	(85.7)	2	(100)
Antiplatelet/anticoagulation therapy, n (%)	20	(83.3)	7		13	(92.9)	0
History of thrombotic events, n (%)	3	(12.5)	1	(12.5)	2	(14.3)	0
History of hemorrhagic events, n (%)	3	(12.5)	2	(25.0)	0		1	(50.0)
Age in the years at the diagnosis of lymphoid neoplasms, median (range)	73.5 (59-92)		68 (59-82)		75.5 (59-92)		71 (69-73)
Duration between the diagnosises of MPNs and lymphoid neoplasms, months in median (range)	68.5 (0-239)		66 (7-105)		84.5 (0-239)		35.5 (9-62)
Lymphoid neoplasms
ML, n (%)	19	(79.2)	8	(100)	9	(64.3)	2	(100)
DLBCL, n (%)	13	(54.1)	6		6		1
EBV-LPD, n (%)	2	(8.3)	0		1		1
FL, n (%)	1	(4.2)	1		0		0
MALT lymphoma, n (%)	1	(4.2)	1		0		0
LPL, n (%)	1	(4.2)	0		1		0
HL, n (%)	1	(4.2)	0		1		0
MM/MGUS, n (%)	4	(16.7)	0		4	(28.6)	0
MM, n (%)	3	(12.5)	0		3		0
MGUS, n (%)	1	(4.2)	0		1		0
CLL/SLL, n (%)	1	(4.2)	0		1	(7.1)	0

MPNs, myeloproliferative neoplasms; ML, malignant lymphoma; DLBCL, diffuse large B-cell lymphoma; EBV, Epstein-Barr virus; LPD, lymphoproliferative disease; FL, follicular lymphoma; MALT, mucosa-associated lymphoid tissue; LPL, lymphoplasmacytic lymphoma; HL, Hodgkin lymphoma; MM, multiple myeloma; MGUS, monoclonal gammopathy of undetermined significance; CLL, chronic lymphatic leukemia; SLL, small lymphocytic B-cell lymphoma; PV, polycythemia vera; ET, essential thrombocythemia; PMF, primary myelofibrosis

*1: Twenty-one patients were analyzed for JAK2V617F mutation.

*2: Eleven patients were analyzed for JAK2V617F mutation.

Table 2. Clinical characteristics of patients with MPNs and DLBCL

	Total (n = 13)
Raw percentages
Male, n (%)	9	(75.0)
Age in years at the diagnosis of MPN, median (range)	70 (52-86)
Type of MPNs
PV	6	(46.2)
ET	6	(46.2)
PMF	1	(7.7)
Age in the years at the diagnosis of lymphoid neoplasms, median (range)	74 (59-92)
Duration between the diagnosises of MPNs and lymphoid neoplasms, months in median (range)	49 (6-195)
Stage
I	2	(15.4)
II	3	(23.1)
III	1	(7.7)
IV	7	(53.8)
Chemotherapy	12
First chemotherapy regimen
R-CHOP	8
Standard dose	4
Reduced dose (50%〜66%)	4
R-THP-COP	3
Reduced dose (60%〜70%)	3
ML5	1
Response to the first chemotherapy regimen
CR	11
PD	1
Reason for the second chemotherapy regimen
PD to the first regimen	1
Relapse after first regimen	3

MPNs, myeloproliferative neoplasms; PV, polycythemia vera; ET, essential thrombocythemia; PMF, primary myelofibrosis; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; R-THP-COP, rituximab, cyclophosphamide, pirarubicin, vincristine, and prednisone; ML5, methotrexate, cytarabine, and prednisone; CR, complete response; PD, progressive disease